Healthcare Global Enterprises Ltd (HCG) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 539787 | NSE: HCG | Hospital & Healthcare Services | Small Cap

HealthcareGlobal Share Price

717.85 1.60 0.22%
as on 05-Dec'25 15:23

Healthcare Global Enterprises Ltd (HCG) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 539787 | NSE: HCG | Hospital & Healthcare Services | Small Cap

DeciZen - make an informed investing decision on HealthcareGlobal

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Healthcare Global Enterprises stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
10,099.1 Cr.
52-wk low:
458.8
52-wk high:
804.3

Is Healthcare Global Enterprises Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of HealthcareGlobal: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Healthcare Global Enterprises Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 4%6.1%7.7%6.1%1.6%-12.6%10.5%8%7.3%6%-
Value Creation
Index
-0.7-0.6-0.5-0.6-0.9-1.9-0.3-0.4-0.5-0.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 4715455866416886098501,0061,0991,2771,308
Sales YoY Gr.-15.7%7.6%9.3%7.5%-11.6%39.6%18.3%9.3%16.1%-
Adj EPS -0.22.320.8-6.1-15.3-3.72.92.42-0.9
YoY Gr.-NA-11.1%-61%-883.3%NANANA-18.4%-16.7%-
BVPS (₹) 6163.569.672.768.569.778.581.584.183.984
Adj Net
Profit
-1.819.317.46.9-54.2-192-51.340.733.327.8-13
Cash Flow from Ops. 57.853.966.48786.370.9124130195146-
Debt/CF from Ops. 3.4444.95.73.40.90.924.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 11.7%13.2%14.5%16.1%
Adj EPS NANANA-16.7%
BVPS3.6%4.1%2.2%-0.3%
Share Price - 37.3% 32.9% 42.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-0.53.62.91.1-8.6-24.9-5.13.62.92.3-1.1
Op. Profit
Mgn %
13.615.21414.716.812.117.316.917.916.616.3
Net Profit
Mgn %
-0.43.531.1-7.9-31.5-64.132.2-1
Debt to
Equity
0.40.40.40.70.80.30.10.10.30.60.3
Working Cap
Days
12813016121124025715012414115380
Cash Conv.
Cycle
-18-16-310223826262321-0

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Healthcare Global Enterprises Ltd.

Standalone Consolidated
TTM EPS (₹) -0.9 2.5
TTM Sales (₹ Cr.) 1,308 2,402
BVPS (₹.) 84 65.3
Reserves (₹ Cr.) 1,043 780
P/BV 8.53 10.97
PE 0.00 285.61
From the Market
52 Week Low / High (₹) 458.80 / 804.30
All Time Low / High (₹) 62.95 / 804.30
Market Cap (₹ Cr.) 10,099
Equity (₹ Cr.) 141
Face Value (₹) 10
Industry PE 90.5

Management X-Ray of HealthcareGlobal:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *3.093.090.003.093.093.093.094.995.705.52
* Pledged shares as % of Promoter's holding (%)

Valuation of HealthcareGlobal - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of HealthcareGlobal

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales4715455866406886098501,0061,1711,277
Operating Expenses 4074625045465735357038379701,065
Manufacturing Costs141158159192215196241273312350
Material Costs134149155153147138210236281318
Employee Cost 8598116130143137157175205221
Other Costs 48577571696595153171177
Operating Profit 6483829411673147169201211
Operating Profit Margin (%) 13.5%15.2%13.9%14.7%16.8%12.1%17.3%16.8%17.1%16.6%
Other Income 372313122412221639
Interest 34162748836343415084
Depreciation 374444477987888997111
Exceptional Items -4030-31-15353-3-16-35
Profit Before Tax -9293713-65-20581585420
Tax -410125-12-1443172116
Profit After Tax -519257-53-1923840334
PAT Margin (%) -1.0%3.6%4.2%1.1%-7.7%-31.5%4.5%4.0%2.8%0.3%
Adjusted EPS (₹)-0.62.32.90.8-6.0-15.32.82.92.40.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 5195446056396078731,0911,1331,1641,169
Share Capital 8586878889125139139139139
Reserves 4344585185515197489529941,0251,030
Minority Interest0000000000
Debt16016521939641921483113375583
Long Term Debt12312421734631514782113274304
Short Term Debt37412501046710101280
Trade Payables97105114106998196109148152
Others Liabilities 6096165259628379374375552699
Total Liabilities 8369101,1031,4001,7541,5471,6441,7302,2392,604

Fixed Assets

Gross Block4675115916931,1411,0581,1771,2751,5661,699
Accumulated Depreciation366999146227313403487592661
Net Fixed Assets 4314424925479147457747889741,038
CWIP 2933791044428593623
Investments 155141219299316366439475506696
Inventories11151716131217212320
Trade Receivables69101126146152147160212221262
Cash Equivalents 5075159151412080237264
Others Assets 91103155280300235129144241302
Total Assets 8369101,1031,4001,7541,5471,6441,7302,2392,604

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 585466878671124130209146
PBT -9293713-65-20581585420
Adjustment 7457609119228579150174227
Changes in Working Capital -0-25-3210-20-49-21-6014-82
Tax Paid -8-71-26-2040-15-17-33-19
Cash Flow From Investing Activity -86-73-185-208-116-24649-138-254-347
Capex -90-40-104-123-80-23-42-95-129-33
Net Investments -3220-154-102189-10-47-112
Others 7-35-100-70-40-120-99-32-78-202
Cash Flow From Financing Activity 120-149166-3236-41-4296-42
Net Proceeds from Shares 271735020453132122
Net Proceeds from Borrowing -110-97910636-219-671416757
Interest Paid -33-12-23-40-66-59-43-36-48-90
Dividend Paid 0000000000
Others -8000762-63-21-25-10
Net Cash Flow 92-33-27-55-3261132-4951-243

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-1.23.674.331.16-8.55-25.873.93.612.860.3
ROCE (%)3.986.127.656.131.62-12.5510.468.027.256.03
Asset Turnover Ratio0.620.620.580.510.440.370.530.60.590.53
PAT to CFO Conversion(x)N/A2.842.6412.43N/AN/A3.263.256.3336.5
Working Capital Days
Receivable Days52577177799066686869
Inventory Days991010876776
Payable Days235248259263256238154159167172

Healthcare Global Enterprises Ltd Stock News

Healthcare Global Enterprises Ltd FAQs

The current trading price of HealthcareGlobal on 05-Dec-2025 15:23 is ₹717.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of HealthcareGlobal stood at ₹10,099.1.
The latest P/E ratio of HealthcareGlobal as of 04-Dec-2025 is 0.00.
The latest P/B ratio of HealthcareGlobal as of 04-Dec-2025 is 8.53.
The 52-week high of HealthcareGlobal is ₹804.3 and the 52-week low is ₹458.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of HealthcareGlobal is ₹1,308 ( Cr.) .

About Healthcare Global Enterprises Ltd

Healthcare Global Enterprises was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company under the Companies Act, 1956. The name of the company was subsequently changed to HealthCare Global Enterprises Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 14, 2005. The company was converted into a public limited company pursuant to a special resolution passed by its Shareholders at the extraordinary general meeting held on May 20, 2006 and the name of the company was changed to HealthCare Global Enterprises Limited. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued by the RoC on July 5, 2006.

The company is a provider of speciality healthcare services in India focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB . Under the “Milann” brand, it operates its fertility centres.

The company’s HCG network operates on a “hub and spoke” model, wherein its HCG centre of excellence in Bengaluru serves as a “hub” to its other cancer centres. Its centre of excellence provides its other centres access to centralised quality control and assurance services; establishes treatment protocols that are adhered to across its HCG network; provides centralised treatment planning and tele-radiology services to help with diagnosis and treatment; conducts weekly central tumour board meetings to review complex cases; and also gives its HCG network access to advanced technologies, such as WBRRS and specialised procedures such as liver transplants and stem cell therapies. This model allows HCG network of cancer centres to leverage the expertise and capabilities of its centre of excellence, which when combined with the diagnostic and treatment facilities at its cancer centres, allows it to deliver quality cancer care to patients across India in a seamless manner.

The company follows a multidisciplinary approach to cancer care across its HCG network, wherein specialist physicians from various disciplines collaborate to provide the best course of treatment for each patient. This allows it to share and develop best practices, build clinical expertise and adopt standardised protocols for diagnosis and treatment, thereby improving the quality of its cancer care services. As a result, the company is able to better serve its patients and ensure consistent clinical outcomes.

Given the large number of patient cases treated across its HCG network, the company is able to efficiently utilise its equipment, technologies and human resources, thereby deriving economies of scale. Furthermore, through the adoption of a centralised drug and consumables formulary, it is able to lower the overall cost of drugs and consumables. Its business model is scalable and when combined with efficient utilisation of resources, it enables it to operate within a competitive cost structure.

Business area of the company

The company is Bangalore based provider of speciality healthcare in India focused on cancer and fertility. It operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed. It also operates fertility centres under the ‘Milann’ brand.

Major events and milestones

  • 2005: Entered into the clinical laboratory business through acquisition of Triesta Sciences Inc. and Triesta Sciences (India) Private Limited.
  • 2006: India Development Fund made its first investment of Rs 500 million in the company,
  • 2006: BMORCL became its subsidiary.
  • 2007: HCG Medi-Surge became its subsidiary.
  • 2007: Evolvence made its first investment of Rs 225 million in the company,
  • 2008: NTICPL made its first investment of Rs 400 million in the company.
  • 2009: Amalgamation of Triesta Sciences (India) Private Limited and Triesta Sciences Inc. with the company.
  • 2010: IL&FS Trust Company Limited a/c MPEF, through its scheme India Build Out Fund I and MAT made its first investment of Rs 312 million in the company.
  • 2011: Amalgamation of BMORCL with the company.
  • 2011: PIOF became a Shareholder by purchasing shares from NTICPL.
  • 2013: V-Sciences made its first investment of Rs 600 million in the company.
  • 2013: Entered into the fertility business through acquisition of 50.10% stake in BACC Healthcare.
  • 2014: Demerger of multispecialty division from HCG Medi-Surge and vesting of the same with the company.
  • 2015: HCG Regency became its subsidiary.
  • 2015: Amalgamation of HCG Vijay with the company.

Awards and accreditations

  • 2010: The company received the ‘Oncology Leader of the Year’ award from Frost and Sullivan.
  • 2011: The company and its Triesta Reference Laboratory received CAP accreditation valid up to August 25, 2015.
  • 2011: The company received the ‘Oncology Leader of the Year’ award from Frost and Sullivan.
  • 2012: HCG cancer centre at Bengaluru received NABH accreditation valid up to May 11, 2018.
  • 2013: The company received the ‘Best Place to Work in Indian Healthcare’ award from People Strong and HOSMAC.
  • 2013: HMS, Ahmedabad received NABH accreditation valid up to June 22, 2016.
  • 2013: Triesta Reference Laboratory received accreditation from the National Accreditation Board for Testing and Caliberation Laboratories for its facilities at HCG Tower, Bengaluru in the field of medical testing valid up to October 13, 2015.
  • 2013: The company was designated an ESMO Designated Centre of Integrated Oncology and Palliative Care.
  • 2013: The company received the ‘Most Innovative Single Specialty Healthcare Entity’ award from VC Circle.
  • 2014: The company received the ‘Golden Peacock Award for Innovation in Management’ from the Institute of Directors.
  • 2014: Its pathology laboratory at HMS received ISO 9001 certification valid up to August 30, 2017.
  • 2015: The company received recognition from the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India for its in-house research and development wing at HCG Tower, Bengaluru.

 

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×